Global Animal pharma market($ 50.89 billion) is expected to grow much faster than human pharma. CAGR 8.8% in 7 to 8 years
API account for 20% market
Innovators are going Asset light
It's a huge opportunity for the first mover in CDMO (Hikal)
And in formulation & API(sequent)
More from Sequent
Cause everyone wanted to buy it at 300+ and no one wants to buy it at 200
Market is short sighted and loves to buy high and sell low
Sequent is a long gestation stock, it won't deliver it's real earnings until FY23-25
Not suitable investment for those who want 100% return/yr
https://t.co/7ytUeSd7gg
Market is short sighted and loves to buy high and sell low
Sequent is a long gestation stock, it won't deliver it's real earnings until FY23-25
Not suitable investment for those who want 100% return/yr
@itsTarH hey Tariq, any idea why is Sequent falling?
— Vivek (@pa_stock) September 27, 2021
https://t.co/7ytUeSd7gg
Don't expect the earnings to go anywhere till FY23.
— Tar \u26a1 (@itsTarH) August 10, 2021
Real growth will only come post FY24.
I expect the stock to either correct or stay muted till then. https://t.co/lUQfzxojTO